Categories Earnings, Health Care

Matinas BioPharma (MTNB): Q4 2019 Earnings Snapshot

pharma stocks
Image for representation (Photo by Drew Hays on Unsplash)

— Matinas BioPharma (NYSE: MTNB) reported loss of $0.04 per share in the fourth quarter of 2019, vs $0.03 per share loss expected. 

— Initiated ENHANCE-IT study of MAT9001 against Vascepa. Topline data expected Q4 2020.

— Cash, cash equivalents and marketable securities at December 31, 2019 were approx. $27.8 million, compared to $12.4 million a year ago. 

— MTNB shares ended down 2.75% in its last trading session on Friday.  

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

General Mills (GIS) Q4 Earnings: Key financials and quarterly highlights

General Mills Inc. (NYSE: GIS) reported fourth quarter 2022 earnings results today. Net sales increased 8% year-over-year to $4.9 billion. Organic net sales rose 13%. Net earnings attributable to General

KB Home (KBH): A look at the homebuilder’s expectations for the year

Shares of KB Home (NYSE: KBH) have dropped 35% year-to-date and 28% over the past 12 months. Last week, the company reported second quarter 2022 earnings results that surpassed expectations

Trade Desk’s stock can strengthen your investment portfolio. Here’s why

Trade Desk, Inc. (NASDAQ: TTD) has remained a much sought-after demand-side platform despite challenging market conditions and growing inflationary pressure, but its stock suffered heavy selling in recent months. The

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top